At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Moxidectin Oral Productdrug
Likely dose
Moxidectin Oral Product 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-blind, Parallel Group Dose Finding Study of Single Oral Doses of Moxidectin in Adults With Scabies
In Brief
A Phase 2 clinical trial evaluating Moxidectin Oral Product for Scabies. Completed, enrolled 22 participants across 5 sites in 3 countries.
Detailed Summary
The effective dose of moxidectin to treat human scabies is not known. This study aims to provide proof of concept that a single dose of moxidectin is effective in eliminating the scabies parasite in humans and to enable the determination of an optimal dose of moxidectin for treatment of scabies for further clinical studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScabies
CountriesAustralia, Austria, France
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 2019
Enrollment StartJan 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedApr 5, 2019
Enrollment StartJan 13, 2020
Primary CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 7.2 years ago
Interventions
Moxidectin Oral Productdrug
The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required